PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) Form 8-K — Nov 4, 2026
PacBio announced Q3 2026 results with revenue of $40.6 million, up from $38.4 million a year ago, driven by 35 Vega system placements (+9% YoY) and growing SPRQ-Nx adoption. GAAP net loss was $37.8 million with GAAP gross margin compressing to 33% from 41% on higher memory costs and Vega manufacturing transition costs. Full-year 2026 revenue guidance was set at $155-160 million. In a separate disclosure, CFO Jim Gibson stepped down effective November 3, 2026, moving to an advisory role through March 31, 2027, with a $500,000 lump-sum payment upon separation.
Key figures
- Revenue
- 40600000
- Guidance
- Full year 2026 revenue expected in the range of $155 million to $160 million
- Total Debt
- 643058000
- Revenue Yoy
- 5.5%
- Total Assets
- 721096000
- Cash Position
- 199400000
- Vega placements
- 35
- Revio placements
- 15
- Gaap gross margin
- 33%
- Revio pull through
- ~$204,000 annualized (vs ~$236,000 prior year)
- Non gaap gross margin
- 36%
- Prior year gaap gross margin
- 41%
- Prior year cash and investments
- 298700000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.